174485-72-4

Usage

Uses

Used in Organic Synthesis:
5-Trifluoromethyl-2-pyridinesulfonyl Chloride is used as a reagent in the field of organic synthesis for its ability to facilitate a range of chemical reactions. Its unique chemical properties allow it to be a versatile component in creating new compounds and molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 5-Trifluoromethyl-2-pyridinesulfonyl Chloride is used as a key intermediate in the development of various drugs. Its role in organic synthesis makes it a valuable asset in the creation of new medications and therapies.
Used in Chemical Research:
5-Trifluoromethyl-2-pyridinesulfonyl Chloride is also utilized in chemical research as a tool to study and understand the behavior of different compounds. Its clear, colorless solution and chemical properties make it an ideal candidate for various experimental procedures.

InChI:InChI=1/C6H3ClF3NO2S/c7-14(12,13)5-2-1-4(3-11-5)6(8,9)10/h1-3H

Upstream product

• 2637-34-5 2-Sulfanylpyridine 
• 76041-72-0 2-mercapto-5-trifluoromethylpyridine 

Downstream Products

• 174484-81-2 tipranavir 
• 174484-81-2 tipranavir 
• 174484-81-2 tipranavir 
• 1378110-16-7 N-(2-(4-(6-fluorobenzo[d]oxazol-2-yl)piperazine-1-carbonyl)phenyl)-5-(trifluoromethyl)pyridine-2-sulfonamide 
• 321679-59-8 4-(5-(trifluoromethyl)pyridin-2-yl)morpholine 
• 296776-84-6 2-(4-methoxyphenyl)-5-(trifluoromethyl)pyridine 
• 105626-77-5 2-phenoxy-5-(trifluoromethyl)pyridine 
• 1189366-29-7 C₁₃H₉F₃N₂O₃S 
• 1141510-06-6 5-trifluoromethylpyridine-2-sulfonic acid hydroxy-{3-[(R)-1-((R)-4-hydroxy-2-oxo-6-phenethyl-6-propyl-5,6-dihydro-2H-pyran-3-yl)propyl]phenyl}amide 
• 1141510-04-4 N-[3-{(1R)-(5,6-dihydro-4-hydroxy-2-oxo-6(R)-phenethyl-6-propyl-2H-pyran-3-yl)-[1-14C]propyl}phenyl]-5-trifluoromethylpyridine-2-sulfonamide 
• 1141509-98-9 N-[3-{(1R)-(5,6-dihydro-4-hydroxy-2-oxo-6(R)-phenethyl-6-propyl-2H-pyran-3-yl)-[1-14C]propyl}phenyl]-5-trifluoromethylpyridine-2-sulfonamide 
• 263842-59-7 5-trifluoromethyl-pyridine-2-sulfonic acid (5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methyl-phenyl)-amide 
• 263842-59-7 (R)-N-(5-tert-butyl-4-{4-hydroxy-6-[2-(4-hydroxyphenyl)ethyl]-6-isopropyl-2-oxo-5,6-dihydro-2H-pyran-3-ylsulfanyl}-2-methylphenyl)-2-(5-trifluoromethylpyridine)sulfonamide 
• 263842-78-0 (R)-5-trifluoromethylpyridine-2-sulfonic acid [5-tert-butyl-4-(4-hydroxy-6-isopropyl-2-oxo-6-phenethyl-5,6-dihydro-2H-pyran-3-ylsulfanyl)-2-methylphenyl]-amide 

Relevant academic research and scientific papers

Desulfonative Suzuki–Miyaura Coupling of Sulfonyl Fluorides

Sulfonyl fluorides have emerged as powerful “click” electrophiles to access sulfonylated derivatives. Yet, they are relatively inert towards C?C bond forming transformations, notably under transition-metal catalysis. Here, we describe conditions under which aryl sulfonyl fluorides act as electrophiles for the Pd-catalyzed Suzuki–Miyaura cross-coupling. This desulfonative cross-coupling occurs selectively in the absence of base and, unusually, even in the presence of strong acids. Divergent one-step syntheses of two analogues of bioactive compounds showcase the expanded reactivity of sulfonyl fluorides to encompass both S?Nu and C?C bond formation. Mechanistic experiments and DFT calculations suggest oxidative addition occurs at the C?S bond followed by desulfonation to form a Pd-F intermediate that facilitates transmetalation.

Transition-Metal-Catalyzed Transformation of Sulfonates via S-O Bond Cleavage: Synthesis of Alkyl Aryl Ether and Diaryl Ether

The catalytic conversion of sulfonates, a versatile class of pharmaceutical intermediates, is usually based on C-O bond cleavage. In this paper, however, we discover a rare transformation of sulfonates via S-O bond cleavage catalyzed by transition metal, through which alkyl sulfonates could undergo an intramolecular desulfitative C-O coupling to form aryl alkyl ethers in the presence of a nickel catalyst. Meanwhile, aryl sulfonates perform similarly to give diaryl ethers catalyzed by a palladium complex. This transformation could tolerate a wide range of functionalities. Controlled experiments reveal that the 2-pyridyl group is necessary to promote the reaction as designed. Crossover experiments proved that this transformation might proceed partly in an intermolecular pathway.

DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY

The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents —C(═O)—, or B represents CH when n=0 and D represents —CH2O— or when n=1 and D represents —O—, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

DERIVATIVES OF HETEROARYLSULFONAMIDES, THEIR PREPARATION AND THEIR APPLICATION IN HUMAN THERAPY

The present invention concerns derivatives of heteroarylsulfonamides, notably as blockers of Kv potassium channels, and more particularly of channels Kv1.5, Kv4.3 or Kv11.1, their application in clinical therapy and their preparation methods. These compounds correspond to the following general formula (I): where R1 represents one or more substituents of the phenyl core X such as: hydrogen, halogen, trifluoromethyl, trifluoromethoxy, linear or branched C1-C4 alkyl, or linear or branched C1-C4 alkoxy, A represents oxygen or sulphur, B represents nitrogen when n=1 or 2 and D represents ?C(=O)-, or B represents CH when n=0 and D represents ?CH2O? or when n=1 and D represents ?O?, R2 represents a hydrogen, a methyl, a fluorine or chlorine atom or a methoxy, HetAr represents a pyridyl or quinolyl group, possibly substituted by a group such as a linear or branched C1-C4 alkyl, a linear or branched C1-C4 alkoxy, a halogen, or a trifluoromethyl, and to their pharmaceutically acceptable salts.

Synthesis of [14C] - and [13C6]-labeled tipranavir and its potential hydroxyl metabolite and the glucuronide conjugate

Tipranavir or Aptivus is a non-peptidic protease inhibitor approved for the combination treatment with ritonavir of HIV infection. Tipranavir labeled with radioactive and stable isotopes of carbon was required for drug metabolism (excretion, distribution,

PPAR-γ modulators

Modulators of PPARγ activity are provided which are useful in pharmaceutical compositions and methods for the treatment of conditions such as type II diabetes and obesity.

5,6-Dihydropyran-2-ones possessing various sulfonyl functionalities: Potent nonpeptidic inhibitors of HIV protease

On the basis of previous SAR findings and molecular modeling studies, a series of compounds were synthesized which possessed various sulfonyl moieties substituted at the 4-position of the C-3 phenyl ring substituent of the dihydropyran-2-one ring system. The sulfonyl substituents were added in an attempt to fill the additional S3' pocket and thereby produce increasingly potent inhibitors of the target enzyme. Racemic and enantiomerically resolved varieties of selected compounds were synthesized. All analogues in the study displayed decent binding affinity to HIV protease, and several compounds were shown to possess very good antiviral efficacy and safety margins. X-ray crystallographic structures confirmed that the sulfonamide and sulfonate moieties were filling the S3' pocket of the enzyme. However, the additional substituent did not provide improved enzymatic inhibitory or antiviral activity as compared to the resolved unsubstituted aniline. The addition of the sulfonyl moiety substitution does not appear to provide favorable pharamacokinectic parameters. Selected inhibitors were tested for antiviral activity in clinical isolates and exhibited similar antiviral activity against all of the HIV-1 strains tested as they did against the wild-type HIV-1. In addition, the inhibitors exhibited good antiviral efficacies against HIV-1 strains that displayed resistance to the currently marketed protease inhibitors.

PYRANONE COMPOUNDS USEFUL TO TREAT RETROVIRAL INFECTIONS

The present invention relates to compounds of formulae (I) and (II) which are pyran-2-ones, 5,6-dihydro-pyran-2-ones, 4-hydroxy-benzopyran-2-ones, 4-hydroxy-cycloalkyl[b]pyran-2-ones, and derivatives thereof, useful for inhibiting a retrovirus in a mammalian cell infected with said retrovirus, wherein R 10 and R 20 taken together are formulae (III) and (IV). STR1